JP7422084B2 - Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 - Google Patents

Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 Download PDF

Info

Publication number
JP7422084B2
JP7422084B2 JP2020553633A JP2020553633A JP7422084B2 JP 7422084 B2 JP7422084 B2 JP 7422084B2 JP 2020553633 A JP2020553633 A JP 2020553633A JP 2020553633 A JP2020553633 A JP 2020553633A JP 7422084 B2 JP7422084 B2 JP 7422084B2
Authority
JP
Japan
Prior art keywords
ret
cancer
composition
fusion
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020553633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520349A5 (enExample
JP2021520349A (ja
Inventor
ラーブ， エリカ エヴァンス
ベニ ビー． ウルフ，
Original Assignee
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66223846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7422084(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2021520349A publication Critical patent/JP2021520349A/ja
Publication of JP2021520349A5 publication Critical patent/JP2021520349A5/ja
Priority to JP2021199945A priority Critical patent/JP2022022391A/ja
Priority to JP2023167564A priority patent/JP2023165937A/ja
Application granted granted Critical
Publication of JP7422084B2 publication Critical patent/JP7422084B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020553633A 2018-04-03 2019-04-03 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 Active JP7422084B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021199945A JP2022022391A (ja) 2018-04-03 2021-12-09 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
JP2023167564A JP2023165937A (ja) 2018-04-03 2023-09-28 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862652284P 2018-04-03 2018-04-03
US62/652,284 2018-04-03
US201862656297P 2018-04-11 2018-04-11
US62/656,297 2018-04-11
US201862657605P 2018-04-13 2018-04-13
US62/657,605 2018-04-13
US201862741683P 2018-10-05 2018-10-05
US62/741,683 2018-10-05
PCT/US2019/025655 WO2019195471A1 (en) 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021199945A Division JP2022022391A (ja) 2018-04-03 2021-12-09 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
JP2023167564A Division JP2023165937A (ja) 2018-04-03 2023-09-28 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤

Publications (3)

Publication Number Publication Date
JP2021520349A JP2021520349A (ja) 2021-08-19
JP2021520349A5 JP2021520349A5 (enExample) 2021-09-30
JP7422084B2 true JP7422084B2 (ja) 2024-01-25

Family

ID=66223846

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020553633A Active JP7422084B2 (ja) 2018-04-03 2019-04-03 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
JP2021199945A Pending JP2022022391A (ja) 2018-04-03 2021-12-09 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
JP2023167564A Withdrawn JP2023165937A (ja) 2018-04-03 2023-09-28 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021199945A Pending JP2022022391A (ja) 2018-04-03 2021-12-09 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
JP2023167564A Withdrawn JP2023165937A (ja) 2018-04-03 2023-09-28 Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤

Country Status (26)

Country Link
US (5) US20210100795A1 (enExample)
EP (2) EP3773589B1 (enExample)
JP (3) JP7422084B2 (enExample)
KR (1) KR20200139749A (enExample)
AU (1) AU2019247766A1 (enExample)
BR (1) BR112020020273A2 (enExample)
CA (1) CA3096043A1 (enExample)
CL (1) CL2020002544A1 (enExample)
CR (1) CR20200522A (enExample)
DK (1) DK3773589T3 (enExample)
ES (1) ES2970041T3 (enExample)
FI (1) FI3773589T3 (enExample)
HR (1) HRP20240124T1 (enExample)
HU (1) HUE065374T2 (enExample)
IL (1) IL277629A (enExample)
LT (1) LT3773589T (enExample)
MX (1) MX2020010417A (enExample)
MY (1) MY203645A (enExample)
PE (1) PE20210096A1 (enExample)
PL (1) PL3773589T3 (enExample)
PT (1) PT3773589T (enExample)
RS (1) RS65127B1 (enExample)
SG (1) SG11202009681YA (enExample)
SI (1) SI3773589T1 (enExample)
WO (1) WO2019195471A1 (enExample)
ZA (1) ZA202006072B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
TWI757256B (zh) 2015-11-02 2022-03-11 美商纜圖藥品公司 轉染過程重排之抑制劑
JP7422084B2 (ja) 2018-04-03 2024-01-25 ブループリント メディシンズ コーポレイション Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
US11946935B2 (en) * 2020-08-25 2024-04-02 Regents Of The University Of Minnesota Circulating tumor markers for meningiomas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079140A1 (en) 2015-11-02 2017-05-11 Blueprint Medicines Corporation Inhibitors of ret

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004174A9 (en) 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
US20060116381A1 (en) 2002-07-24 2006-06-01 Fagin James A 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
BRPI0608910A2 (pt) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
WO2006128042A2 (en) 2005-05-26 2006-11-30 The Johns Hopkins University Methods of identifying mutations in nucleic acid
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP1978958A4 (en) 2006-01-24 2009-12-02 Merck & Co Inc RET tyrosine kinase Inhibition
EP2036557B1 (en) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
EP2074118A2 (en) 2007-07-09 2009-07-01 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CA2693967A1 (en) 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
WO2010006432A1 (en) 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
EP2411011A4 (en) 2009-03-24 2012-08-15 Msd Kk NEW AMINO-PYRIDINE DERIVATIVES WITH SELECTIVE AURORA A INHIBITION
JP2012529513A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
US8877924B2 (en) 2009-06-09 2014-11-04 NantBio Inc. Benzyl substituted triazine derivatives and their therapeutical applications
WO2011053938A1 (en) 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
NZ599041A (en) 2009-11-13 2014-05-30 Genosco Kinase inhibitors
IN2014DN01605A (enExample) 2011-08-04 2015-05-15 Nat Cancer Ct
CA2846197C (en) 2011-08-23 2024-01-16 Foundation Medicine, Inc. Kif5b-ret fusion molecules and uses thereof
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013133367A1 (ja) 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 新規トリアジン誘導体
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
BR112014026283B1 (pt) 2012-04-25 2022-08-02 Raqualia Pharma Inc Compostos da fórmula (i), (ii), (iii), uso dos mesmos, composição farmacêutica, e processo para a preparação de uma composição farmacêutica
WO2013170159A1 (en) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
JPWO2014017491A1 (ja) 2012-07-26 2016-07-11 国立研究開発法人国立がん研究センター Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子
CN104703600A (zh) 2012-09-07 2015-06-10 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
SI2902029T1 (sl) 2012-09-25 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Inhibitor ret
US9604980B2 (en) 2012-11-07 2017-03-28 Nerviano Medical Sciences S.R.L. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
SG11201506445PA (en) 2013-02-25 2015-09-29 Bristol Myers Squibb Co C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
SMT201700152T1 (it) 2013-03-15 2017-05-08 Glaxosmithkline Ip Dev Ltd Derivati piridinici come inibitori della chinasi riarrangiata durante la trasfezione (ret)
WO2014147640A2 (en) 2013-03-19 2014-09-25 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of anagliptin
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
CN105658814A (zh) 2013-08-20 2016-06-08 日本国立癌症研究中心 在肺癌中检测出的新型融合基因
WO2015057873A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CR20170093A (es) 2014-09-10 2017-07-17 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de ret (reorganizado durante la transfección)
ES2819871T3 (es) 2014-09-10 2021-04-19 Glaxosmithkline Ip Dev Ltd Compuestos utilizados como inhibidores de la quinasa reordenada durante la transfección (RET)
CA2967125C (en) 2014-11-14 2022-10-25 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CN104844567B (zh) 2015-04-23 2017-03-29 暨南大学 一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
AU2016311426B2 (en) 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
EP3371208B8 (en) 2015-11-02 2024-10-23 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
JP2018534933A (ja) 2015-11-02 2018-11-29 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用
EP3377497A1 (en) 2015-11-19 2018-09-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
CN109069512B (zh) 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
EP3442977B1 (en) 2016-04-15 2023-06-28 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
PT3442535T (pt) 2016-04-15 2022-09-05 Cancer Research Tech Ltd Compostos heterocíclicos como inibidores da ret quinase
RS62322B1 (sr) 2016-04-15 2021-10-29 Cancer Research Tech Ltd Heterociklična jedinjenja kao inhibitori ret kinaze
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN106749231B (zh) 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 萘啶化合物和药物组合物及它们的应用
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
EP3624802A1 (en) 2017-05-15 2020-03-25 Blueprint Medicines Corporation Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
WO2018237134A1 (en) 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (zh) 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用
WO2019008172A1 (en) 2017-07-07 2019-01-10 Nipd Genetics Public Company Limited ENRICHED MULTIPLEXED PARALLEL ANALYSIS IN TARGET FOR TUMOR BIOMARKER EVALUATION
CN107980784B (zh) 2017-12-13 2020-05-26 中国农业大学 5-氨基吡唑类化合物在调节植物生长方面的应用
JP7194188B2 (ja) 2017-12-19 2022-12-21 ターニング・ポイント・セラピューティクス・インコーポレイテッド 疾患を治療するための大環状化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN108341782A (zh) 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 3-氨基-5-甲基吡唑的合成工艺
JP7422084B2 (ja) 2018-04-03 2024-01-25 ブループリント メディシンズ コーポレイション Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
CN111440151A (zh) 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
CN111362923A (zh) 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
AR124245A1 (es) 2020-12-04 2023-03-01 Blueprint Medicines Corp Método para preparar pralsetinib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079140A1 (en) 2015-11-02 2017-05-11 Blueprint Medicines Corporation Inhibitors of ret

Also Published As

Publication number Publication date
US20210100799A1 (en) 2021-04-08
EP3773589A1 (en) 2021-02-17
AU2019247766A1 (en) 2020-10-15
EP4353317A2 (en) 2024-04-17
SI3773589T1 (sl) 2024-03-29
JP2022022391A (ja) 2022-02-03
ZA202006072B (en) 2024-01-31
CA3096043A1 (en) 2019-10-10
PT3773589T (pt) 2024-02-06
HRP20240124T1 (hr) 2024-04-12
SG11202009681YA (en) 2020-10-29
HUE065374T2 (hu) 2024-05-28
RU2020135917A (ru) 2022-05-04
PL3773589T3 (pl) 2024-04-02
MY203645A (en) 2024-07-11
PE20210096A1 (es) 2021-01-12
WO2019195471A1 (en) 2019-10-10
KR20200139749A (ko) 2020-12-14
LT3773589T (lt) 2024-02-12
US20250041297A1 (en) 2025-02-06
JP2023165937A (ja) 2023-11-17
EP4353317A3 (en) 2024-05-08
DK3773589T3 (da) 2024-01-29
FI3773589T3 (fi) 2024-02-01
US20210085680A1 (en) 2021-03-25
BR112020020273A2 (pt) 2021-04-06
ES2970041T3 (es) 2024-05-24
US11963958B2 (en) 2024-04-23
US20220175773A1 (en) 2022-06-09
US11273160B2 (en) 2022-03-15
EP3773589B1 (en) 2023-11-01
MX2020010417A (es) 2021-01-08
RS65127B1 (sr) 2024-02-29
IL277629A (en) 2020-11-30
US20210100795A1 (en) 2021-04-08
US11872192B2 (en) 2024-01-16
CR20200522A (es) 2021-02-17
CL2020002544A1 (es) 2021-06-11
JP2021520349A (ja) 2021-08-19

Similar Documents

Publication Publication Date Title
JP7422084B2 (ja) Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
US20210290620A1 (en) Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
CN106211755B (zh) 使用erk和raf抑制剂的组合的癌症治疗
JP7490635B2 (ja) Ｅｇｆｒ変異がんの処置
Alvarez et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification
CN111032082A (zh) Her2阳性癌症的治疗
Ono et al. Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity
WO2013170182A1 (en) Treating cancer with an hsp90 inhibitory compound
JP2024528705A (ja) がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法
WO2019200252A1 (en) Non-invasive detection of response to immunotherapy
JP2020531467A (ja) 神経内分泌腫瘍を処置する方法
EP2991650A1 (en) Methods for the treatment of cancer
RU2800951C2 (ru) Ингибитор ret для применения в лечении рака, имеющего ret-альтерацию
Pircher et al. Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient
HK40046992A (en) Ret inhibitor for use in treating cancer having a ret alteration
HK40046992B (en) Ret inhibitor for use in treating cancer having a ret alteration
CN119604291A (zh) Blu-945联合奥斯替尼治疗非小细胞肺癌
EP2204177B1 (en) Cancer marker and therapeutic agent for cancer
EP4183393A1 (en) Compounds for treating hepatocellular carcinoma
Nicola et al. Emerging therapeutics for radioiodide-refractory thyroid cancer
Wisniewski et al. Dual inhibition of EGFR and PI3Kinase signaling in EGFR amplified triple negative breast cancer cells induces apoptosis and reduces tumor growth
WO2023002362A1 (en) Treatment of hematological malignancy
Quattrone Selected genes involved in GIST evolution from indolent to advanced tumours

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210715

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220425

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220519

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220523

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220524

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220610

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240115

R150 Certificate of patent or registration of utility model

Ref document number: 7422084

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150